Clinical Trial – A Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma – Hodgkin Lymphoma

BeiGene is running a clinical trial to test drugs called BGB-A317 to treat Hodgkin Lymphoma. The study is to evaluate the efficacy of BGB-A317 assessed by Independent Review Committee (IRC) in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification.

The drug is BGB-A317.

Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 68 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Actual Study Start Date : April 21, 2017
Estimated Primary Completion Date : August 2018
Estimated Study Completion Date : January 2019

For enrollment please visit www.clinicaltrials.gov.

* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.